Fujifilm to Expand CMP Slurry Production Capacity in the United States - Business Wire

CMP slurry is not a commodity chemical; it is formulation IP that gates yield below 5nm. Fujifilm's US capacity build is an IP-jurisdiction maneuver, not a logistics play. The physical carrier of proprietary nanoparticle recipes is being relocated into US legal territory—a sovereign-asset decision disguised as supply-chain optimization. Technically, a single advanced wafer traverses 15-20 CMP steps, each demanding distinct silica or ceria particle sizes from 20 to 200 nm. Localizing production tilts upstream feedstock sourcing toward North America and tightens the formulation-process-yield feedback loop for Intel, TSMC Arizona, and Samsung Taylor, creating an exclusionary flywheel that structurally penalizes non-local suppliers. On compliance, CHIPS Act tax credits shave roughly 15-20% off capex, but the real driver is the irreversibility of cross-border recipe-data exposure under tightening export controls. Once formulation parameters sit outside allied jurisdiction, leakage risk is asymmetric and permanent. Competitively, Entegris and Merck face a 12-month window to match North American capacity or lose local-supply qualification at major US fabs. The market will shift from global-recipe-regional-filling to regional-recipe-regional-production, pushing industry ASPs up 8-12%. Over 24 months, this playbook will be replicated across photoresist, wet chemicals, and sputtering targets. Semiconductor materials de-globalization is now irreversible, and the resulting cost premium will become a permanent structural disadvantage for US chip manufacturing.